Salvianolic acid A, a natural plant compound, reduced atherosclerosis plaque in mice by targeting aging cells in blood vessel walls, according to a 2026 research study published in Advanced Science. The compound works by blocking a protein called HSP90 alpha, which normally protects these problematic aging cells. When HSP90 alpha was blocked, the aging cells died and plaque size decreased while plaque stability improved, suggesting a potential new treatment approach for heart disease.
Researchers have discovered that salvianolic acid A, a natural compound found in certain plants, may help fight atherosclerosis, a disease where fatty buildup narrows arteries. According to Gram Research analysis, the compound works by targeting aging cells in blood vessel walls that contribute to plaque formation. In laboratory and animal studies, the treatment reduced plaque size and made artery walls more stable. While these results are promising, human trials are needed to confirm whether this plant-based approach could become a new treatment option for heart disease.
Key Statistics
A 2026 research article in Advanced Science found that salvianolic acid A reduced plaque burden and increased plaque stability in mice with atherosclerosis by targeting aging cells in blood vessel walls through HSP90 alpha inhibition.
In genetically modified mice, blocking the HSP90 alpha protein mimicked the protective effects of salvianolic acid A against atherosclerosis, proving that this protein is the critical target for the compound’s disease-fighting mechanism.
When researchers artificially increased HSP90 alpha levels in treated mice, the protective effects of salvianolic acid A completely disappeared, confirming that HSP90 alpha inhibition is essential for the compound’s ability to reduce atherosclerosis progression.
The Quick Take
- What they studied: Whether a natural plant compound called salvianolic acid A could reduce atherosclerosis, the buildup of fatty deposits in arteries that leads to heart disease.
- Who participated: Laboratory experiments used human cells from blood vessel walls, plus mice genetically engineered to develop atherosclerosis when fed a high-fat diet.
- Key finding: Salvianolic acid A reduced plaque buildup in mouse arteries and made the plaque more stable by targeting aging cells in vessel walls, suggesting the compound may slow atherosclerosis progression.
- What it means for you: This research suggests a potential new plant-based treatment approach for atherosclerosis, though human studies are needed before any clinical use. People with heart disease should continue following their doctor’s current treatment plans.
The Research Details
This research combined laboratory experiments with animal studies. First, scientists grew human blood vessel cells in dishes and treated them with salvianolic acid A to see how the compound affected aging cells. They also created versions of cells with more or less of a specific protein called HSP90 alpha to understand which proteins the compound targets. Next, they used mice that naturally develop atherosclerosis when eating a high-fat diet. These mice received salvianolic acid A treatment while also having their genes modified to increase or decrease HSP90 alpha levels in their blood vessel cells. Researchers then examined the mice’s arteries to measure plaque size and stability.
The study design allowed researchers to test both how the compound works at the cellular level and whether those effects translate to real disease improvement in living animals. By using genetically modified mice, they could prove that HSP90 alpha is the key target responsible for the compound’s protective effects.
This approach, combining cell studies with animal models, is standard for early-stage drug research and helps determine whether a promising compound deserves further investigation in humans.
Understanding exactly how salvianolic acid A works is crucial before testing it in people. By identifying HSP90 alpha as the target, researchers can explain the mechanism and potentially develop even better treatments. The animal studies provide evidence that the compound actually reduces disease in a living system, not just in isolated cells.
The research was published in Advanced Science, a peer-reviewed journal that publishes high-quality studies. The researchers used multiple experimental approaches to confirm their findings, including tests with cells that had the target protein removed or added back. This repetition strengthens confidence in the results. However, the study was conducted only in laboratory and animal settings, not in humans, so results may not directly apply to people.
What the Results Show
Salvianolic acid A successfully reduced the number of aging cells in blood vessel walls by activating a cellular stress response. The compound worked by blocking a protein called HSP90 alpha, which normally protects aging cells from dying. When HSP90 alpha was blocked, another protein called AKT was broken down, and a stress-response pathway called PERK was activated. This combination triggered aging cells to self-destruct.
In mice with atherosclerosis, treatment with salvianolic acid A reduced the overall plaque burden and made existing plaques more stable. A stable plaque is less likely to rupture and cause a heart attack. The protective effects were strongest when the mice also had reduced HSP90 alpha levels in their blood vessel cells, confirming that blocking this protein is essential for the compound’s benefits.
When researchers artificially increased HSP90 alpha levels in the treated mice, the protective effects of salvianolic acid A disappeared. This finding proves that HSP90 alpha is the critical target. The results suggest that salvianolic acid A works by forcing aging cells to undergo a controlled death process, which reduces the number of problematic cells contributing to atherosclerosis.
The compound increased contact between mitochondria, the energy centers of cells, and the endoplasmic reticulum, a cellular structure involved in protein production. This increased contact allowed more calcium to enter mitochondria, which appears to trigger the cell death process. These secondary effects help explain the complete mechanism of how salvianolic acid A works at the molecular level.
Previous research showed that salvianolic acid A has general cardiovascular protective effects, but this study is the first to explain specifically how it works against atherosclerosis. The finding that aging cells drive atherosclerosis aligns with recent research showing that senescence, or cellular aging, plays a major role in heart disease. This study adds to growing evidence that targeting aging cells could be an effective treatment strategy.
This research was conducted entirely in laboratory dishes and mice, not in humans. Mouse models of atherosclerosis do not perfectly replicate the disease in people. The study did not test different doses of salvianolic acid A or compare it to existing atherosclerosis medications. Long-term safety and effectiveness in humans remain unknown. Additionally, the sample size for animal studies was not specified in the abstract, making it difficult to assess statistical power.
The Bottom Line
Based on current evidence, salvianolic acid A cannot yet be recommended as a treatment for atherosclerosis in humans. The research is promising but preliminary. People with atherosclerosis should continue following their doctor’s prescribed treatments, which may include statins, blood pressure medications, and lifestyle changes. Further human clinical trials are necessary before any new recommendations can be made.
This research is most relevant to cardiologists, pharmaceutical researchers, and people interested in plant-based approaches to heart disease. People with atherosclerosis or family history of heart disease may find this research interesting as a potential future option, but current treatments remain the standard of care. This is not yet applicable to general health recommendations.
If salvianolic acid A advances to human trials, it typically takes 5 to 10 years of research before a new treatment becomes available to patients. Early-stage research like this study represents the first step in that long process.
Frequently Asked Questions
What is salvianolic acid A and where does it come from?
Salvianolic acid A is a natural compound found in red sage, a plant used in traditional Chinese medicine. Researchers extracted and studied this compound to understand its effects on heart disease, specifically atherosclerosis caused by aging cells in blood vessel walls.
Can I take salvianolic acid A supplements to prevent atherosclerosis?
Not yet. This research is preliminary and only tested in laboratory cells and mice. Human clinical trials have not been conducted, so salvianolic acid A is not approved as a medical treatment. Continue following your doctor’s current atherosclerosis treatment plan.
How does salvianolic acid A work differently from current heart disease medications?
Current medications like statins lower cholesterol, while salvianolic acid A targets aging cells that contribute to plaque formation. The compound forces these problematic cells to die by blocking a protective protein called HSP90 alpha, representing a different approach to fighting atherosclerosis.
When will salvianolic acid A be available as a treatment for patients?
This research is in early stages. If development continues successfully, human clinical trials would typically take 5 to 10 years before any potential approval. Many promising compounds never reach patients, so availability remains uncertain.
Is this research applicable to humans with atherosclerosis right now?
No. The study used laboratory cells and mice, not humans. Results in animals do not always translate to people. Significant additional research, including human trials, is needed before salvianolic acid A could be recommended for atherosclerosis treatment.
Want to Apply This Research?
- Users interested in heart health could track daily intake of foods containing salvianolic acid A, such as red sage root used in traditional medicine, alongside their current atherosclerosis medications and lifestyle changes. Log weekly plaque-related symptoms like chest discomfort or shortness of breath to monitor disease progression.
- While awaiting human trials, users can support cardiovascular health by tracking adherence to prescribed medications, monitoring blood pressure and cholesterol levels weekly, and logging heart-healthy behaviors like exercise and diet quality. This creates a baseline for comparing any future salvianolic acid A treatment effects.
- Establish a long-term tracking system for cardiovascular markers including blood pressure, cholesterol levels, and symptom frequency. If salvianolic acid A becomes available through clinical trials, users can compare these metrics before and after treatment to assess personal effectiveness.
This article summarizes research findings and is not medical advice. Salvianolic acid A has not been approved by the FDA or other regulatory agencies for treating atherosclerosis in humans. Do not stop or change any prescribed heart disease medications without consulting your doctor. If you have atherosclerosis or cardiovascular disease, work with your healthcare provider to determine the most appropriate treatment plan for your individual situation. This research represents early-stage laboratory and animal studies that may not apply to human health.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.